Enlivex Therapeutics Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Enlivex Therapeutics Ltd. generated cash of -$23,523,000, which is more than the previous year. Cash used in financing activities reached the amount of $360,000 last year. Net change in cash is therefore -$49,131,000.
Cash Flow
| 2014 | -4.40M | -22.06M | 36.78M |
|---|---|---|---|
| 2015 | -13.24M | 9.95M | 36.78M |
| 2016 | -15.48M | 8.98M | 6.08M |
| 2017 | -6.35M | 3.00M | 8.05K |
| 2018 | -3.16M | -533K | 5.19M |
| 2019 | -7.04M | -6.35M | 8.30M |
| 2020 | -11.00M | -20.97M | 33.08M |
| 2021 | -17.54M | -38.40M | 60.98M |
| 2022 | -23.95M | 62.52M | 150K |
| 2023 | -23.52M | -25.96M | 360K |
ENLV Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 50.35M | 11.63M | 7.01M | 5.52M | 9.79M | 9.00M | 6.87M | 7.28M | 10.58M | 270K |
Operating activities | ||||||||||
Net income | -29.06M | -31.06M | -14.46M | -11.82M | -9.38M | -4.24M | -5.94M | -16.02M | -15.36M | -7.02M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 835K | 777K | 546K | 286K | 206K | 121K | 64K | 38K | 17K | 5K |
Stock-based compensation expense | 1.95M | 2.71M | 2.91M | 670K | 810K | 0 | 408K | 700K | 2.62M | 736K |
| Deferred income tax benefit | 1.95M | 2.71M | 2.91M | 670K | 810K | 0 | 408K | 700K | 2.62M | 736K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 608K | 278K | -1.24M | 1.82M | 41K | -130K | 567K | 399K | -786K | -245K |
Inventories | 0 | -278K | 1.24M | -1.82M | -41K | 0 | -790K | 0 | 0 | 0 |
Accounts payable | -1.12M | 1.16M | 442K | 36K | 114K | 145K | -681K | -712K | 234K | 2.14M |
Cash generated by operating activities | -23.52M | -23.95M | -17.54M | -11.00M | -7.04M | -3.16M | -6.35M | -15.48M | -13.24M | -4.40M |
Investing activities | ||||||||||
Purchases Of Investments | -26.16M | -1.60M | -104.41M | -19.95M | -7.71M | -40K | 0 | 0 | 0 | -22M |
Investments In Property Plant And Equipment | -236K | -8.12M | -1.62M | -1.01M | -193K | -461K | -2K | -18K | -48K | -63K |
Acquisitions Net | 0 | -9.70M | -20.03M | 0 | 1.54M | 0 | 9K | 0 | 0 | 0 |
Cash generated by investing activities | -25.96M | 62.52M | -38.40M | -20.97M | -6.35M | -533K | 3.00M | 8.98M | 9.95M | -22.06M |
Financing activities | ||||||||||
Common Stock Issued | 360K | 150K | 53.17M | 24.46M | 7.70M | 5.19M | 0 | 6.08M | 0 | 36.78M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 360K | 150K | 60.98M | 33.08M | 8.30M | 5.19M | 8.05K | 6.08M | 36.78M | 36.78M |
Net Change In Cash | -49.13M | 38.72M | 4.62M | 1.48M | -4.26M | 731K | -3.34M | -415K | -3.29M | 10.31M |
Cash at end of period | 1.22M | 50.35M | 11.63M | 7.01M | 5.52M | 9.73M | 3.52M | 6.87M | 7.28M | 10.58M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |